Researchers Contribute to Symposium on Emerging Research in Nutrition and Metabolic Conditions
Purchase, NY, April 19, 2004 (NASDAQ: NXXI) -- Nutrition 21’s lead nutrition and biochemistry researcher, Dr. Vijaya Juturu, presented a scientific overview on the role of chromium in insulin resistance today at the Annual Conference of the Federation for American Societies of Experimental Biology (FASEB) in Washington, DC. Dr. Juturu outlined the latest research contributions to understanding how chromium picolinate may help combat the epidemic of insulin resistance and related conditions such as Metabolic Syndrome, obesity, type 2 diabetes and cardiovascular disease.
Dr. Juturu was invited to present at the meeting’s Nutrition and Metabolism Program, and offered an overview of 30+ years of laboratory and clinical research conducted around the globe, which indicates:
- Chromium is an essential mineral required for proper insulin function
- An inverse relationship between chromium levels in the body and insulin-related diseases
- Nutritional supplementation with chromium, especially in the form of chromium picolinate, enhances insulin sensitivity and blood glucose levels in people with insulin resistance and type 2 diabetes
- Chromium appears to potentiate the action of insulin to stimulate glucose transport into cells
- Recent data suggest that chromium may facilitate insulin signaling by activating Akt, an intracellular protein involved in insulin signal transduction.
“The exchange with the scientific community at FASEB will help advance the dialogue about the benefits of chromium picolinate supplementation in addressing the epidemic of diabetes and obesity,” said James Komorowski, MS, Vice President of Research and Scientific Affairs for Nutrition 21. “The body of evidence suggests that chromium, especially in the form of chromium picolinate, can help restore normal glucose metabolism and may help prevent insulin resistance.”
Insulin resistance is believed to affect up to one in three Americans. It is predicted that one of the most significant developments for the future diabetes market will be a wider range of drugs aimed at reversing insulin resistance (Diabetes Drugs of Tomorrow Report 2000, Datamonitor).
“The chromium link to insulin resistance is the foundation of Nutrition 21’s business strategy,” said Gail Montgomery, President and CEO. “As the research unfolds, we believe that Nutrition 21 is uniquely positioned to participate in the growing market for treatment of insulin resistance and type 2 diabetes, by providing chromium-based supplements as an adjunct nutritional therapy that is safe, convenient and cost-effective. Currently, there is no pharmaceutical treatment approved for Metabolic Syndrome.”
In addition to the chromium presentation, Nutrition 21 scientists reported several study results at FASEB, including animal data investigating the safety and impact of supplementation with Diachrome™ (chromium picolinate and biotin) on metabolic health in animals. The Company also presented early safety data associated with one of its new, patented technologies, a unique arginine complex.
“Our research platform continues to focus on metabolic health, and we anticipate the release of new clinical data associated with patented uses of our therapeutic products, Chromax® and Diachrome™, in the months ahead,” concluded Montgomery.
About Nutrition 21
Nutrition 21 is a nutritional bioscience company and the maker of chromium-based nutritional supplements whose health benefits are substantiated by clinical research. The company markets Chromax® chromium picolinate, the leading brand of nutritional chromium, and Diachrome™, a nutritional supplement for people with type 2 diabetes. Diachrome is composed of chromium picolinate and biotin, and is available through diabetes educators. Nutrition 21 holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at www.nutrition21.com
# # #